BOARD OF DIRECTORS

  • Kenneth Bate

    Independent Director
    Kenneth Bate has served as a member of our Board of Directors since January 2014, and as Chairman since February 2016. From May 2009 until January 2012, Mr. Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr. Bate was President and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr. Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From January 2005 to March 2006, Mr. Bate was employed at JSB-Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies that he co-founded. From 2002 to January 2005, Mr. Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Mr. Bate served as a member of the Board of Directors of Cubist Pharmaceuticals, a public biopharmaceutical company, from June 2003 to January 2015 and was its non-executive Chair from March 2011 to January 2015. Mr. Bate is a director of five other public biopharmaceutical companies, AVEO Pharmaceuticals, Genocea Biosciences, Epizyme Pharmaceuticals, Vanda Pharmaceuticals and Madrigal Pharmaceuticals. During the last five years, Mr. Bate also served as a director of NitroMed and Coley Pharmaceutical Group. He holds an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in chemistry from Williams College.
    Financial Expert
  • Joanne T. Beck, Ph.D.

    Chief Operating Officer, Boston Pharmaceuticals
    Joanne T. Beck, Ph.D. has served as a member of our Board of Directors since February 2019. Dr. Beck is currently the Chief Operating Officer at Boston Pharmaceuticals. From 2016 to 2019, Dr. Beck was the Executive Vice President of Global Pharmaceutical Development and Operations and a member of the Executive Committee at Celgene. From 2012 to 2016, Dr. Beck was Senior Vice President of Pharmaceutical Development at Shire. Prior to Shire, she held positions of increasing responsibility in Abbott’s Global Pharmaceutical Operations and was the site head of Abbott Vascular Instruments GmbH. Prior to Abbott, Dr. Beck held positions in Process Development at both Genentech and Amgen. Dr. Beck serves on the board of directors for Orchard Therapeutics. She holds a BA in Chemistry from Lewis and Clark College, a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.
  • Fred Callori

    Senior Vice President, Corporate Development, Xontogeny; Perceptive Advisors
    Fred Callori has served on our Board of Directors since January 2021. Since September 2017, Mr. Callori has served as Senior Vice President, Corporate Development at Xontogeny, LLC, life sciences accelerator. Mr. Callori is also a partner in the Perceptive Xontogeny Venture Fund. Prior to Xontogeny and Perceptive, Mr. Callori was a Partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart, LLP. Mr. Callori holds a J.D. from Boston University School of Law and a B.A. in Economics from Binghamton University. 
  • Hugh M. Cole

    Chief Business Officer and Head of Corporate Development, Jounce Therapeutics
    Hugh M. Cole has served as a member of our Board of Directors since July 2019. Mr. Cole is currently the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics. From 2014 to 2017, Mr. Cole was the Chief Business Officer at ARIAD Pharmaceuticals. Prior to ARIAD Pharmaceuticals, he held positions of increasing responsibility at Shire Pharmaceuticals, most recently Senior Vice President, Strategic Planning and Program Management from 2012 to 2014, Global Franchise Leader from 2009 to 2012, and head of Business Development for Shire’s rare disease business from 2007 to 2009. Prior to Shire, Mr. Cole held various positions in Business Development at Oscient Pharmaceuticals and Millennium Pharmaceuticals. Mr. Cole holds an AB in Chemistry from Harvard University and an MBA in Health Care Management and Finance from the Wharton School at the University of Pennsylvania.
  • Michael Kishbauch

    Independent Director
    Michael Kishbauch has served as a member of our board of directors since April 2016. Mr. Kishbauch previously served as President and Chief Executive Officer of Achillion from July 2004 until his retirement in September 2013. Prior to that, he founded and served as President and Chief Executive Officer of OraPharma, Inc., a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson & Johnson in 2003, from 1996 to 2004. Mr. Kishbauch also held senior management positions with MedImmune, Inc., a biotechnology company, from 1992 to 1995. Mr. Kishbauch formerly served as a director of Achillion Pharmaceuticals, Progenics Pharmaceuticals, Inc. and TetraLogic Pharmaceuticals Corporation. Mr. Kishbauch holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.
  • Gregg Lapointe

    Chief Executive Officer, Cerium Pharmaceuticals
    Gregg Lapointe has served as a member of our Board of Directors since January 2019. Since 2012, Mr. Lapointe has served as Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, a privately-held biopharmaceutical company. He previously held varying roles at Sigma-Tau Pharmaceuticals, Inc., a privately held biopharmaceutical company, from 2001 through 2012, including Chief Operating Officer from 2003 to 2008 and Chief Executive Officer from 2008 to 2012. From 1996 to 2001, Mr. Lapointe served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Mr. Lapointe previously served as a member of the Board of Directors of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Pharmaceutical Research Manufacturers of America (PhRMA), Plus Therapeutics, Inc., and Questcor Pharmaceuticals, Inc. He currently serves on the Board of Directors of two other public biopharmaceutical companies, Soligenix, Inc. and Rigel Pharmaceuticals, Inc. He holds an MBA from Duke University, a Graduate Diploma in Accountancy from McGill University, a Bachelor of Commerce from Concordia University and is a Certified Public Accountant (Illinois).
    Financial Expert
  • Jill Milne, Ph.D.

    Co-Founder and Chief Executive Officer
      Jill Milne, Ph.D. is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.
      • Jonathan Violin, Ph.D.

        President and Chief Executive Officer, Viridian Therapeutics
        Jonathan Violin has served on our Board of Directors since January 2021. Dr. Violin is a co-founder of Quellis, and prior to the merger was its Treasurer and Secretary since December 2018. Dr. Violin has served as President and Chief Executive Officer of Viridian Therapeutics, Inc. (formerly Miragen Therapeutics, Inc.), a publicly traded biotechnology company, since January 2021, and was previously President and Chief Operating Officer of Viridian, from October 2020 until January 2021. Dr. Violin co-founded Viridian Therapeutics, Inc., a privately held biotechnology company (which was acquired by Miragen Therapeutics, Inc.) leading its operations since its founding in 2020. Dr. Violin also co-founded Dianthus Therapeutics, Inc., a biotechnology company, in May 2019, and co-founded and helped lead Trevana Inc., a biotechnology company, in various roles from 2008 until November 2018, most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr. Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, a Master of Business Administration with a concentration in Health Sector Management from the Fuqua School of Business, and a Bachelor of Sciences in Chemical Pharmacology from Duke University.